Arne Trummer
Overview
Explore the profile of Arne Trummer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stratmann J, Althoff F, Doebel P, Rauh J, Trummer A, Hunerliturkoglu A, et al.
Eur J Cancer
. 2024 Feb;
201:113911.
PMID: 38377774
Background: Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the...
2.
Springer C, Krauter J, Trummer A
Oncotarget
. 2023 Dec;
14:949-956.
PMID: 38039414
In myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily...
3.
Eder L, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, et al.
Curr Oncol
. 2023 Jan;
30(1):1146-1150.
PMID: 36661736
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing...
4.
Trummer A, Schier W, Krauter J, Hannig H, Christmann J
Leuk Res Rep
. 2022 Dec;
18:100359.
PMID: 36457814
Resistance mutations can be detected in 75% of CLL patients progressing under BTK inhibitor therapy. Using semiquantitative wild-type-blocking (WTB) RT-PCR for BTK and Sanger sequencing for PLCG2 mutations, we compared...
5.
Trummer A, Bethge A, Dickgreber N, Dittrich I, Golpon H, Hoffknecht P, et al.
Lung Cancer
. 2022 Nov;
174:141-145.
PMID: 36402005
Objectives: For refractory NSCLC patients with EGFR mutations, recent studies have demonstrated a favorable response to the combination of anti-angiogenic therapy and checkpoint inhibition but included only very few patients...
6.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, et al.
Blood Adv
. 2021 Jul;
5(13):2707-2716.
PMID: 34196677
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate...
7.
Shahswar R, Beutel G, Gabdoulline R, Koenecke C, Markel D, Eder M, et al.
Ann Hematol
. 2020 Jul;
100(2):595-599.
PMID: 32705308
No abstract available.
8.
Weidner C, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, et al.
Oncotarget
. 2016 Feb;
7(10):10765-72.
PMID: 26909595
Dyskeratosis congenita (DKC) is associated with impaired telomere maintenance and with clinical features of premature aging. In this study, we analysed global DNA methylation (DNAm) profiles of DKC patients. Age-associated...
9.
Harms A, Fuehner T, Warnecke G, Haverich A, Gottlieb J, Trummer A
Transplantation
. 2015 Oct;
99(11):2394-400.
PMID: 26451527
Background: Chronic lung allograft dysfunction (CLAD) is the major outcome limitation for lung transplant recipients (LTR) after the first year, and therapies targeting immunological pathways show only limited success. Because...
10.
Werwitzke S, Vollack N, von Hornung M, Kalippke K, Kutzschbach J, Trummer A, et al.
Thromb Haemost
. 2015 Aug;
114(6):1127-35.
PMID: 26245154
Development of inhibitory antibodies against factor VIII (FVIII) is a severe complication of replacement therapy in haemophilia A. Patients with inhibitors are treated with high FVIII doses in the context...